20
Participants
Start Date
October 8, 2021
Primary Completion Date
April 30, 2024
Study Completion Date
October 30, 2024
hPSC-CM Therapy
Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 200 million hPSC-CMs in 2.5-5 mL medium suspension will be injected into the myocardium.
HelpThera, Nanjing
Lead Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
OTHER
Help Therapeutics
INDUSTRY